DexCom Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.

Country	United States
Founded	1999
Industry	Electromedical and Electrotherapeutic Apparatus
Employees	9,600
CEO	Kevin Sayer

Contact Details

Address: 6340 Sequence Drive San Diego, Delaware 92121 United States
Phone	858 200 0200
Website	dexcom.com

Stock Details

Ticker Symbol	0A4M
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	3845

Key Executives

Name	Position
Kevin Sayer	Chief Executive Officer
Jereme Sylvain	Chief Financial Officer
Jacob Leach	Chief Operating Officer
Sean Christensen	Head of Investor Relations